Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-22T07:56:20.920Z Has data issue: false hasContentIssue false
  • English
  • Français

Reducing Dosage in Maintenance Treatment of Schizophrenia

Review and Prognosis

Published online by Cambridge University Press:  06 August 2018

Nina R. Schooler
Nina R. Schooler*
Affiliation:
University of Pittsburgh, School of Medicine, Western Psychiatric Institute & Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

This paper reviews the assumptions and efficacy of two strategies for dose reduction during maintenance treatment in schizophrenia: low dose and targeted medication. Studies of low-dose treatment suggest that it can be used for relatively short periods of time or if the dosage reduction is moderate. Studies of targeted treatment suggest that relapse risk increases significantly compared with standard-dose treatment and that there are few offsetting advantages. The paper also reports initial findings from the NIMH Treatment Strategies in Schizophrenia Study, which compares low dose, targeted treatment and a standard dose in the context of two forms of family treatment. Early stabilisation of patients is lower than expected, but patient characteristics are useful in predicting likelihood of stabilisation.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 163 , Issue S22: The Psychopharmacology of Schizophrenia , December 1993 , pp. 58 - 65
Copyright
Copyright © 1993 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). Washington, DC: APA.Google Scholar
Andreasen, N. C. (1982) Negative symptoms in schizophrenia. Archives of General Psychiatry, 39, 784–788.CrossRefGoogle ScholarPubMed
Baldessarini, R. J., Cole, J. O., Davis, J. M., et al (1981) Tardive Dyskinesia Task Force Report 18. Washington, DC: American Psychiatric Association.Google Scholar
Caffey, E. M. Jr, Diamond, L. S., Frank, T. V., et al (1964) Discontinuation or reduction of chemotherapy in chronic schizophrenics. Journal of Chronic Disease, 17, 347–358.CrossRefGoogle ScholarPubMed
Carpenter, W. T. Jr, Hanlon, T. E., Heinrichs, D. W., et al (1990) Continuous vs. targeted medication in schizophrenic outpatients: outcome results. American Journal of Psychiatry, 147, 1138–1148.Google Scholar
Davis, J. M. (1975) Overview: maintenance therapy in psychiatry –I. Schizophrenia. American Journal of Psychiatry, 132, 1237–1245.Google Scholar
Falloon, I. R. H., Boyd, J. L. & McGill, C. W. (1984) Family Care of Schizophrenia: a Problem Solving Treatment for Mental Illness. New York: Guilford Press.Google Scholar
Falloon, I. R. H., Boyd, J. L. & McGill, C. W., et al (1985) Family management in the prevention of morbidity of schizophrenia. Archives of General Psychiatry, 42, 887–896.CrossRefGoogle ScholarPubMed
Glick, I. D., Jacobs, M., Lieberman, J., et al (1989) Prediction of short term outcome in schizophrenia: depressive symptoms, negative symptoms, and extrapyramidal signs. Psychopharmacology Bulletin, 25, 344–347.Google Scholar
Goldstein, M. J., Rodnick, E. H., Evans, J. R., et al (1978) Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry, 35, 1169–1177.CrossRefGoogle ScholarPubMed
Hargreaves, W. A., Kane, J. M., Ninan, P. T., et al (1989) Demographic characteristics, treatment history, presenting psychopathology and early course in schizophrenia. Psychopharmacology Bulletin, 25, 340–343.Google ScholarPubMed
Herz, M. I. & Melville, C. (1980) Relapse in schizophrenia. American Journal of Psychiatry, 137, 801–805.Google Scholar
Herz, M. I., Szymanski, H. V. & Simon, J. C. (1982) Intermittent medication for stable schizophrenic outpatients: an alternative to maintenance medication. American Journal of Psychiatry, 139, 918–922.Google ScholarPubMed
Herz, M. I., Glazer, W. M., Moster, M. A., et al (1991) Intermittent vs. maintenance medication in schizophrenia. Archives of General Psychiatry, 48, 333–339.Google Scholar
Hogarty, G. E., Anderson, C. M., Reiss, D. J., et al (1986) Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare of schizophrenia. Archives of General Psychiatry, 43, 633–642.CrossRefGoogle ScholarPubMed
Hogarty, G. E., McEvoy, J. P., Munetz, M., et al (1988) Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Archives of General Psychiatry, 45, 797–805.CrossRefGoogle ScholarPubMed
Johnson, D. A. W., Ludlow, J. M., Street, K., et al (1987) Double-blind comparison of half-dose and standard flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. British Journal of Psychiatry, 151, 634–638.CrossRefGoogle ScholarPubMed
Jolley, A. G., Hirsch, S. R., McRink, A., et al (1989) Trial of brief intermittent prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. British Medical Journal, 298, 985–990.Google Scholar
Jolley, A. G., Hirsch, S. R., Morrison, E., et al (1990) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients – clinical and social outcome at two years. British Medical Journal, 301, 837–842.Google Scholar
Kane, J. M., Rifkin, A., Woerner, M., et al (1983) Low-dose neuroleptic treatment of outpatient schizophrenics. Archives of General Psychiatry, 40, 893–896.Google Scholar
Kane, J. M., Rifkin, A., Woerner, M., et al (1985) High dose vs. low dose strategies in the treatment of schizophrenia. Psychopharmacology Bulletin, 21, 533–537.Google Scholar
Kane, J. M., Woerner, M. & Sarantakos, S. (1986) Depot neuroleptics: a comparative review of standard, intermediate, and low dose regimens. Journal of Clinical Psychiatry, 47 (suppl.), 30–33.Google ScholarPubMed
Keith, S. J., Bellack, A., Frances, A., et al (1989) The influence of diagnosis and family treatment on acute treatment response and short term outcome in schizophrenia. Psychopharmacology Bulletin, 25, 336–339.Google Scholar
Keith, S. J., Matthews, S. M. & Schooler, N. R. (1991) A review of psychoeducational family approaches. In Advances in Neuropsychiatry and Psychopharmacology, Vol. I. Schizophrenia Research (eds Tamminga, C. A. & Schulz, S. C.), pp. 247–254. New York: Raven Press.Google Scholar
Leff, J., Kuipers, L., Berkowitz, R., et al (1985) A controlled trial of social intervention in the families of schizophrenic patients: two year follow up. British Journal of Psychiatry, 146, 594–600.Google Scholar
Marder, S. R., Van Putten, T., Mintz, J., et al (1984) Costs and benefits of two doses of fluphenazine. Archives of General Psychiatry, 41, 1025–1029.Google Scholar
Marder, S. R., Van Putten, T., Mintz, J., et al (1987) Low and conventional dose maintenance therapy with fluphenazine decanoate: two year outcome. Archives of General Psychiatry, 44, 518–521.Google Scholar
Pietzcker, A., Gaebel, W., Kopcke, W., et al (1986) A German multi-center study on the neuroleptic long-term therapy of schizophrenic patients: preliminary report. Pharmacopsychiatry, 19, 161–166.CrossRefGoogle Scholar
Prien, R. F. (1984) Long term maintenance pharmacotherapy in recurrent and chronic affective disorders. In The Chronically Mentally Ill: Research and Services (ed. Mirabi, M.), pp. 159–174. New York: Spectrum.Google Scholar
Schooler, N. R. (1985) Treatment of schizophrenia: maintenance strategies and pharmacologic tactics. In Controversies in Schizophrenia (ed. Alpert, M.), pp. 366–380. New York: Guilford Press.Google Scholar
Schooler, N. R. (1991) Maintenance medication for schizophrenia: strategies for dose reduction. Schizophrenia Bulletin, 17, 311–324.Google Scholar
Schooler, N. R., Keith, S. J., Severe, J. B., et al (1989) Acute treatment response and short term outcome in schizophrenia. Psychopharmacology Bulletin, 25, 331–335.Google Scholar
Simpson, G. M. & Angus, J. W. S. (1970) Drug-induced extrapyramidal disorders. Acta Psychiatrica Scandinavica (suppl.), 212, 17–19.Google Scholar
Wistedt, B., Wiles, D. & Kolakowska, T. (1981) Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet, i, 1163.Google Scholar
Woerner, M. G., Mannuza, S. & Kane, J. M. (1988) Anchoring the BPRS: an aid to improved reliability. Psychopharmacology Bulletin, 24, 112–117.Google ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.